Biotech

▲ Peaking Business

Definium's LSD-based anxiety, depression drug scores another trial win

4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

4 sources 4 articles v 2 1d ago

◼ Archived Business 🔮 fades ✓

Takeda’s long-serving R&D chief Andy Plump to retire in wake of pipeline successes

Takeda Pharmaceutical's R&D chief Andy Plump is set to retire in June 2027 following a period of significant pipeline reorganization and regulatory success.

7 sources 8 articles v 5 6d ago

◼ Archived Business 🔮 fades ✓

How Novartis' Double-Stacked Failures Shook Biotech

Novartis is facing significant scrutiny within the biotech sector following a series of dual failures that have impacted investor confidence.

1 sources 1 articles v 0 8d ago

◼ Archived Business 🔮 fades ✗

Novartis Stock Tanks Following Third Major Pipeline Setback

Novartis stock experiences a sharp decline following a Phase 3 failure for a dystrophy drug linked to its $12 billion Avidity acquisition.

1 sources 1 articles v 0 8d ago

◼ Archived Business 🔮 holds ✗

Roivant’s $14M bet on Bayer’s inhaled hypertension med pays off with phase 2 win

Roivant Sciences stock surges as its experimental inhaled lung disease drug hits mid-stage study goals.

8 sources 9 articles v 6 9d ago

◼ Archived Business 🔮 fades ✗

Inhibrx claims first win for long-sought immunotherapy target

Inhibrx claims a first-of-its-kind win for a long-sought immunotherapy target with new clinical data.

9 sources 9 articles v 7 8d ago

◼ Archived Business 🔮 fades ✓

Novartis stock slides as centerpiece of $12B Avidity buyout flunks ‘crucial’ phase 3 test

Novartis shares experienced their worst single-day drop in over two decades following the failure of a crucial phase 3 trial for an Avidity buyout drug.

4 sources 6 articles v 3 9d ago

◼ Archived Business 🔮 holds ✗

Personalized mRNA cancer vaccines offer new hope. We explain

Personalized mRNA cancer vaccines are gaining momentum following Phase III success in melanoma and expanded global clinical trials.

9 sources 9 articles v 7 10d ago

◼ Archived Business 🔮 holds ✗

Teva autoimmune antibody notches ph. 2 win in celiac disease

Teva's experimental antibody TEV-408 meets its primary goal in a mid-stage celiac disease trial.

9 sources 9 articles v 7 14d ago

◼ Archived Business 🔮 fades ✗

Novartis inks $3.2B subcutaneous delivery deal with Alteogen

Novartis has entered a multi-billion dollar agreement to utilize Alteogen's subcutaneous drug delivery technology.

13 sources 13 articles v 12 14d ago

◼ Archived Business 🔮 fades ✗

Roche inks $1.53B deal for Simcere’s B-cell-targeting antibody

Roche has secured a global licensing pact with Simcere Zaiming for an experimental B-cell-targeting antibody.

15 sources 18 articles v 17 15d ago

◼ Archived Business 🔮 holds ✓

Three deaths in CAR-T trials prompt halt by Novartis; Bristol Myers programs also paused

Novartis and Bristol Myers Squibb halt multiple CAR-T clinical trials for autoimmune diseases following patient deaths and safety reviews.

12 sources 12 articles v 10 15d ago

◼ Archived Business 🔮 holds ✗

Trump reportedly plans to announce new drug pricing deals with nearly a dozen drugmakers

9 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

9 sources 9 articles v 34 17d ago

◼ Archived Business 🔮 fades ✓

Eli Lilly to Buy Merida Biosciences for Up to $2.875 Billion

Eli Lilly is expanding its autoimmune portfolio through the acquisition of Merida Biosciences in a deal valued at up to $2.875 billion.

8 sources 8 articles v 8 17d ago

◼ Archived Business 🔮 fades ✓

China is a Threat to Biotech’s Massive Bull Run

5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

6 sources 6 articles v 4 20d ago

◼ Archived Business 🔮 holds ✗

F.D.A. Approves Drug Poised to Transform Care for Pancreatic Cancer

8 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

8 sources 8 articles v 28 22d ago

◼ Archived Business 🔮 fades ✓

Vacant lab space, shrinking workforce put Mass. in ‘unique position’ for biotech bounceback

7 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

7 sources 7 articles v 5 23d ago

◼ Archived Business 🔮 fades ✗

FDA Approves Alzheimer’s Blood Test Developed by Roche and Eli Lilly

The FDA has granted clearance to a first-of-its-kind blood test for Alzheimer's biomarkers developed through a partnership between Roche and Eli Lilly.

14 sources 14 articles v 13 22d ago

◼ Archived Business 🔮 fades ✓

Moderna, Merck breakthrough could usher in wave of cancer vaccines

11 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

14 sources 22 articles v 21 18d ago

◼ Archived Business 🔮 fades ✓

EyePoint Stock Craters 69% After Drug Trial Failure. It May Be an Overreaction.

2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

2 sources 2 articles v 1 30d ago

◼ Archived Business 🔮 fades ✗

The Surprising Reason This Biotech Plummeted 69%

Eyepoint Pharmaceuticals stock has plummeted 69% following a late-stage trial failure for its wet AMD drug, DURAVYU.

10 sources 12 articles v 9 30d ago

◼ Archived Business 🔮 fades ✓

Biotech company co-founded by top autoimmune researcher lays out plans with antibody therapies

1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

1 sources 1 articles v 0 35d ago

◼ Archived Business 🔮 fades ✓

Biotech Scores Again With LSD In Anxiety; Stock Rises

3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

3 sources 3 articles v 1 35d ago

◼ Archived Business 🔮 fades ✗

Deerfield-backed Boulevard Bio embarks on ‘beautiful path to a cure’ with trio of immunology drugs

Deerfield-backed startup Boulevard Bio launches with $65M and a trio of immunology drugs targeting autoimmune cures.

8 sources 8 articles v 6 35d ago

◼ Archived Business 🔮 fades ✗

Regeneron backs $75M series A for antibody upstart Infinimmune

7 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

7 sources 7 articles v 5 36d ago

◼ Archived Business 🔮 fades ✗

Why Sionna Therapeutics Stock Is Crashing 91% to a Record Low

3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

3 sources 3 articles v 1 37d ago

◼ Archived Business 🔮 fades ✓

MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial

MoonLake Immunotherapeutics reports that its nanobody drug, sonelokimab, successfully met all clinical endpoints in a Phase 3 trial for psoriatic arthritis.

5 sources 5 articles v 3 38d ago

◼ Archived Business 🔮 holds ✗

FDA approves Replimune melanoma drug previously rejected twice

The FDA has granted accelerated approval to Replimune's melanoma drug Tudriqev following a yearlong regulatory clash.

9 sources 11 articles v 8 41d ago

◼ Archived Science 🔮 fades ✗

Gene-edited beagles may offer a future option for people with dog allergies

Kindred Companion Sciences has used CRISPR gene-editing to create hypoallergenic beagles by removing a major allergy-causing protein.

22 sources 24 articles v 28 38d ago

◼ Archived Business 🔮 holds ✗

FDA Panel Votes In Favor of Replimune’s Melanoma Treatment

Replimune shares surge following a favorable FDA advisory panel vote for its melanoma treatment.

12 sources 14 articles v 12 48d ago

◼ Archived Business 🔮 fades ✗

MapLight shares sink on mixed ph. 2 schizophrenia readout

7 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

7 sources 8 articles v 5 51d ago

◼ Archived Business 🔮 fades ✗

Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug

FDA scientists are disputing efficacy claims regarding Capricor Therapeutics' Phase 3 Duchenne muscular dystrophy cell therapy, triggering a stock plunge.

10 sources 11 articles v 9 51d ago

◼ Archived Business 🔮 holds ✗

Argenx to Buy Forte Biosciences for $2.2 Billion

10 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

10 sources 10 articles v 8 52d ago

◼ Archived Business 🔮 fades

Trump Administration Live Updates: F.D.A. Advisers Hold More Meetings on Poorly Understood Peptides

FDA advisers vote to loosen rules on poorly understood peptides, sparking talk of a biotech gold rush.

4 sources 4 articles v 4 55d ago

◼ Archived Business 🔮 fades

Why Arrowhead Shot Sky-High, While Chief Rival Ionis Toppled

Arrowhead stock surges to multi-year highs following a major Phase 3 trial success, while chief rival Ionis falls.

8 sources 8 articles v 6 57d ago

◼ Archived Business 🔮 fades

The 'Surprisingly Soft' Unit That Caused Danaher To Plummet

Danaher shares plummeted up to 14% following Q2 results, as a 'surprisingly soft' business unit overshadowed a beat in earnings and revenue.

9 sources 11 articles v 8 57d ago

◼ Archived Business 🔮 fades

Tempus AI Scoops Up Personalis For $1.5 Billion; But Shares Dive

Tempus AI is acquiring cancer-monitoring firm Personalis in a deal valued at approximately $1.5 billion, though market reaction has been negative.

7 sources 7 articles v 5 58d ago

◼ Archived Business 🔮 fades

Kalshi Will Offer Sports-Style Betting on Drug Trial Results

Prediction market Kalshi is expanding its platform to allow users to wager on biotech clinical trial outcomes and FDA regulatory decisions.

9 sources 10 articles v 8 63d ago

◼ Archived Business 🔮 fades

Eli Lilly nears deal to buy psychedelic drugmaker AtaiBeckley, Bloomberg News reports

Eli Lilly is entering the psychedelic drug market with a deal to acquire AtaiBeckley for up to $3.8 billion to treat resistant depression.

9 sources 14 articles v 11 63d ago

◼ Archived Business 🔮 fades

Why This Biotech Stock, With Its First FDA Approval, Just Crashed By Double Digits

Celcuity shares plummeted double digits despite the FDA granting the company its first-ever drug approval for advanced breast cancer treatment.

8 sources 9 articles v 6 63d ago

◼ Archived Business 🔮 fades

Biogen defends anti-tau drug after stock slides on Alzheimer’s readout

Biogen defends its anti-tau drug following a stock decline triggered by a recent Alzheimer's treatment readout.

2 sources 2 articles v 1 64d ago

◼ Archived Business 🔮 fades

Q32’s stock jumps 60% on latest phase 2 alopecia data for potential rival to JAK inhibitors

Q32 Bio (QTTB) shares surged following positive phase 2 clinical trial results for its alopecia areata drug, Bempikibart.

9 sources 10 articles v 8 65d ago

◼ Archived Business 🔮 fades

A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss

Novo Nordisk and Vivani are partnering to develop a long-acting semaglutide implant designed to improve weight loss adherence for up to a year.

5 sources 5 articles v 3 68d ago

◼ Archived Business 🔮 fades

Vertex Pharma Makes A $10 Billion Deal; Crinetics Stock Doubles

Vertex Pharma's $10 billion purchase of Crinetics sparks a near‑doubling of its shares and a biotech‑M&A surge

7 sources 9 articles v 6 71d ago

◼ Archived Business 🔮 fades

Breaking: Vertex makes $10B deal for commercial endocrinology biotech Crinetics

7 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

7 sources 9 articles v 6 72d ago

◼ Archived Business 🔮 holds

Novartis to Buy Myricx Bio for Up to $1.5 Billion

8 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

8 sources 8 articles v 6 73d ago

◼ Archived Health 🔮 fades

How a new fungal genome-editing tool could open fresh paths to cancer treatments

A prime‑editing tool for filamentous fungi is producing novel anti‑cancer compounds, drawing biotech attention.

5 sources 6 articles v 3 75d ago

◼ Archived Business 🔮 fades

Scribe Therapeutics files for IPO in test of public appetite for earlier-stage biotechs

Scribe Therapeutics seeks $75 million in an IPO, testing market appetite for early-stage biotech.

5 sources 5 articles v 3 75d ago

◼ Archived Health 🔮 fades

‘World’s most contagious disease’ on track for highest US cases in 35 years

Measles cases in the United States have surpassed 2,000 in 2026, threatening the nation's measles-free status as infections reach a 35-year high.

9 sources 12 articles v 9 76d ago

◼ Archived Business 🔮 holds

FDA’s top gene therapy regulator is leaving his role

11 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

11 sources 12 articles v 10 78d ago

◼ Archived Business 🔮 fades

Sangamo to put ‘substantially all’ assets for sale in bankruptcy, lines up Lilly and Astellas as buyers

8 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

8 sources 8 articles v 6 85d ago

◼ Archived Business 🔮 holds

FDA to launch pilot program to speed up early-stage clinical trials

10 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

10 sources 10 articles v 40 87d ago

◼ Archived Business 🔮 fades

Biotech Goes Sky-High After LSD Drug Treats Depression

5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

5 sources 5 articles v 14 87d ago

◼ Archived Business 🔮 fades

AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio

AbbVie has announced a $10.9 billion acquisition of Apogee Therapeutics to expand its immunology drug portfolio.

6 sources 7 articles v 4 87d ago

◼ Archived Business 🔮 fades

AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports

6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

6 sources 6 articles v 4 88d ago

◼ Archived Business 🔮 fades

Why Biotech Stocks Are Celebrating This Nail-Biter

2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

2 sources 2 articles v 1 91d ago

◼ Archived Business 🔮 fades

FDA panel considers a first-of-its-kind flu vaccine using mRNA technology

An FDA advisory committee has unanimously backed Moderna's mRNA-based flu vaccine, marking a significant development for the technology.

9 sources 10 articles v 8 89d ago

◼ Archived Business 🔮 holds

Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.

13 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

13 sources 13 articles v 12 91d ago

◼ Archived Business 🔮 fades

The Surprising FDA View That Sent Moderna Stock Flying

Moderna stock prices increased following positive feedback from the FDA regarding the company's mRNA influenza vaccine candidate.

9 sources 10 articles v 8 92d ago

◼ Archived Business 🔮 fades

‘I wouldn’t call it a blip’: Biotech IPOs here to stay after another record-breaking listing

1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

1 sources 1 articles v 0 96d ago